- Ascletis Pharma recently reported that its next-generation triple peptide agonist ASC37 achieved greater weight loss than tirzepatide in diet‑induced obese mice, and outlined plans to file investigational new drug applications for both once‑monthly subcutaneous and oral formulations in the third quarter of 2026.
- The company also highlighted that ASC37 and its dual agonist ASC35 qualify as biologics, potentially benefiting from longer U.S. exclusivity and reduced exposure to government price negotiations compared with small‑molecule obesity drugs.
- Against this backdrop, we will explore how ASC37’s biologic status and extended half‑life profile could reshape Ascletis Pharma’s broader investment narrative.
Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution
Advertisement
What Is Ascletis Pharma’s Investment Narrative?
For Ascletis Pharma, being a shareholder really comes down to believing that its dense obesity and metabolic pipeline can eventually justify ongoing losses and a rich price‑to‑book multiple, despite minimal current revenue and pressure on earnings. The latest ASC37 data add an intriguing twist: a biologic triple agonist showing stronger weight loss than tirzepatide in mice, paired with a long half‑life and potential U.S. exclusivity advantages. That does not change the near‑term catalysts, which still hinge on ASC30’s clinical progress, the upcoming interim results on August 31, and execution across multiple early‑stage assets. But it does nudge the story toward a higher‑risk, higher‑optionality profile, where future value may depend on how quickly ASC37 and ASC35 move from promising preclinical biology to human proof‑of‑concept.
However, there is one emerging risk here that investors should not ignore.
Upon reviewing our latest valuation report, Ascletis Pharma’s share price might be too optimistic.
Exploring Other Perspectives
The single fair value estimate from the Simply Wall St Community sits far below the current price, underlining how cautious at least some private investors are. Set that against the ASC37 biologic upside and ongoing losses, and you can see why views on Ascletis’ long‑term payoff differ so widely.
Explore another fair value estimate on Ascletis Pharma – why the stock might be worth less than half the current price!
Decide For Yourself
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts
- A great starting point for your Ascletis Pharma research is our analysis highlighting 2 important warning signs that could impact your investment decision.
- Our free Ascletis Pharma research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Ascletis Pharma’s overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
The market won’t wait. These fast-moving stocks are hot now. Grab the list before they run:
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow.
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
- Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free
• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks
Try a Demo Portfolio for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
About SEHK:1672
Ascletis Pharma
A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China
See The Free Research Report
Flawless balance sheet with limited growth
See The Free Research Report
Market Insights
What does frontier-beating open source mean for AI investors?Andrew Legget
Why 2026’s worst-looking sector might be its most misreadMitchell Lawler
A brand’s strength doesn’t always lastRichard Bowman
Advertisement
Weekly Picks
CE
Ceazaron Sparc AI·3 months ago
When GPS fails: this small cap is fixing a $54B drone problem
Fair Value:CA$5.2552.0% undervalued
136followersusers have followed this narrative
·0commentsusers have commented on this narrative
·26likesusers have liked this narrative
BL
BlackGoaton IREN·17 days ago
IREN’s Bold Moves in Sustainable Bitcoin Mining & AI Data Centers
Fair Value:US$71.4848.5% undervalued
227followersusers have followed this narrative
·10commentsusers have commented on this narrative
·33likesusers have liked this narrative
HE
HedgeYon Arm Holdings·19 days ago
The Architecture Layer of AI Computing – But Priced Like the Future Already Arrived?
Fair Value:US$43044.3% undervalued
28followersusers have followed this narrative
·1commentusers have commented on this narrative
·8likesusers have liked this narrative
HI
Hidden_Rock_Capitalon Fiserv·about 1 month ago
Temporary “perfect storm” leads to opportunity to buy financial services leader for less than 5x long-term earnings
Fair Value:US$119.9955.0% undervalued
38followersusers have followed this narrative
·1commentusers have commented on this narrative
·11likesusers have liked this narrative
RecentlyUpdated Narratives
RI
richard_byrneon Apple·about 2 hours ago
Strip Out The Refunds And The Quarter Was In Line
Fair Value:US$279.9910.3% overvalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
DA
davidlsanderon Optimi Health·about 3 hours ago
The Picks and Shovels of PsychedelicMedicine: Optimi Health (NASDAQ: OPTH)
Fair Value:CA$0.361.8k% overvalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
13
13111yon Taylor Wimpey·about 3 hours ago
Million-Home Hope for Taylor Wimpey?
Fair Value:UK£1.0525.7% undervalued
14followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
OS
oscargarciaon NVIDIA·2 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century
Fair Value:US$28028.3% undervalued
235followersusers have followed this narrative
·9commentsusers have commented on this narrative
·16likesusers have liked this narrative
CU
CubanEroson Microsoft·about 1 month ago
A wonderful business at reasonable price
Fair Value:US$419.9110.7% overvalued
110followersusers have followed this narrative
·0commentsusers have commented on this narrative
·7likesusers have liked this narrative
TR
tripledubon Alphabet·about 13 hours ago
Warren Buffett Just Bet $10 Billion on Google. The Catch? You May Already Be Too Late
Fair Value:US$202.6275.8% overvalued
125followersusers have followed this narrative
·1commentusers have commented on this narrative
·18likesusers have liked this narrative
